Praziquantel

Praziquantel is the medicine the world relies on against schistosomiasis, a disease caused by blood flukes that lives in fresh water across much of Africa, Asia, the Middle East and South America. It also treats the liver flukes linked to bile duct cancer, the lung fluke and several tapeworms, and more than 100 million people a year receive it in school and community campaigns. For forty years nobody knew exactly how it worked; in 2019 and 2021 laboratory teams traced its action to a calcium channel in the worm's body. This page reports what the label, the trials, the reviews and the World Health Organization state, each claim tied to a source listed at the bottom. Decisions about any medicine belong with a clinician.

Table of Contents

  1. What Praziquantel Is
  2. Discovery and History
  3. How It Acts: A Calcium Channel in the Worm
  4. How the Body Handles It
  5. Schistosomiasis: The Main Use
  6. Liver Flukes, Lung Flukes and Tapeworms
  7. Mass Drug Administration and the 2022 World Health Organization Guideline
  8. Young Children and Arpraziquantel
  9. Falling Cure Rates and Resistance Research
  10. Cancer: What the Research Does and Does Not Show
  11. Safety Findings
  12. What Is Not Known
  13. Connections
  14. Key Research Papers
  15. Featured Videos

What Praziquantel Is

Praziquantel is a synthetic drug, made in a chemical plant rather than extracted from a plant or microbe. Chemically it is an isoquinolinone (Colley and colleagues, 2014) — a compact ring-shaped molecule. The United States label describes it as an "anthelmintic, trematodicide": a drug against parasitic worms, and specifically against trematodes, the flat, leaf-shaped worms called flukes. It is a white crystalline powder that is practically insoluble in water and sold in the United States as a 600 milligram film-coated tablet with three score lines, so it can be broken into four 150 milligram pieces and dosed by body weight.

Praziquantel works against two groups of flatworms: the flukes (blood flukes, liver flukes, lung flukes and intestinal flukes) and the cestodes, or tapeworms. It is also not effective against one important fluke, Fasciola hepatica, the sheep liver fluke (Park and colleagues, 2021); the World Health Organization's Model List of Essential Medicines lists a different drug, triclabendazole, among its anti-fluke medicines.

A mirror-image pair in one tablet

Praziquantel molecules come in two mirror-image forms, like a left and a right hand. Standard tablets contain an equal mix of both, called a racemate. The worm-killing activity belongs mainly to one form, called R-praziquantel (Park and colleagues, 2019). A 2011 chemistry paper noted that the inactive form "is associated with side effects and is responsible for the extremely bitter taste of the pill" (Woelfle and colleagues, 2011). That observation led to arpraziquantel, a children's tablet containing only the active form, described further down this page.

Human and veterinary relatives

Praziquantel is used in both human and animal medicine. A 2023 review of fifty years of research notes that it remains the drug of choice for schistosomiasis in people and is "used in many combinations with antinematode drugs in veterinary medicine" (Waechtler and colleagues, 2023) — that is, mixed with roundworm drugs in deworming products for dogs, cats, horses and other animals. Veterinary products are made and labelled for animals, in strengths and forms that differ from the human tablet.

Discovery and History

According to the 2023 review, work on praziquantel began about fifty years earlier as a collaboration between two German pharmaceutical companies (Waechtler and colleagues, 2023). The founding paper on its use against schistosomes appeared in 1977: Gönnert and Andrews reported detailed experiments in mice, multimammate rats and Syrian hamsters infected with Schistosoma mansoni, the main intestinal blood fluke of people.

Their findings already contained most of what is known today about the drug's strengths and weak spot. Praziquantel worked by mouth and by injection, against male and female worms alike. Splitting the total dose into three or more portions in one day roughly doubled its effect compared with a single dose. It was very effective against the larvae that had just entered the skin, "less effective against 2- to 4-week-old juveniles", and fully effective again against worms five weeks old and older. The authors concluded that "praziquantel promises to be a very potent antischistosomal drug" (Gönnert and Andrews, 1977).

The United States label gives an initial approval year of 1982. Over the following decades praziquantel replaced older schistosomiasis drugs; a 2014 Cochrane review of urinary schistosomiasis found that it "has the strongest evidence base" of any drug studied for that infection (Kramer and colleagues, 2014). By 2014, reviewers described praziquantel as "currently the only available antischistosomal drug", distributed "mainly through mass administration programs to millions of people every year" (Cioli and colleagues, 2014). The World Health Organization's 2025 Model List of Essential Medicines lists praziquantel three times: as an intestinal worm medicine, as an anti-fluke medicine and, on the complementary list, as a medicine for cysticercosis.

How It Acts: A Calcium Channel in the Worm

Soon after contact with praziquantel, a schistosome clenches into a rigid spasm and its outer skin, called the tegument, blisters and breaks up. The current United States label still describes this effect and then states: "the mechanism of action is unknown." The label describes the drug as causing "a rapid contraction of schistosomes by a specific effect on the permeability of the cell membrane" and "vacuolization and disintegration of the schistosome tegument."

The 2019 and 2021 discoveries

In 2019 a laboratory team reported that praziquantel switches on an ion channel in the schistosome — a pore in the cell membrane that lets calcium flow into cells. The channel belongs to the transient receptor potential melastatin (TRPM) family, and the team named the schistosome version the praziquantel-sensitive transient receptor potential melastatin channel. Its behaviour matched what was known about the drug: it responded to tiny (nanomolar) amounts of praziquantel, it responded to the active R-form far more than to the other form, it produced sustained calcium signals, and its activation matched the muscle spasm and skin damage seen in treated worms (Park and colleagues, 2019). This was laboratory work on worm cells and isolated channels.

In 2021 the same group showed how praziquantel fits into a water-repelling pocket within the channel, which opens it, lets calcium flood in, and paralyses the worm. The drug also activated the matching channel in other praziquantel-sensitive flukes, but not in Fasciola hepatica — and when the researchers changed a single building block (amino acid) of the Fasciola channel to match the schistosome version, it became sensitive to praziquantel. The authors concluded that, after decades of clinical use, the molecular basis of the drug's action at this channel had been resolved (Park and colleagues, 2021).

The same year, a separate genetics team bred laboratory schistosomes that survive praziquantel and searched their genomes for the cause. The strongest signal pointed to the same calcium channel: resistant worms made less of it, chemicals that block the channel made worms more resistant, and chemicals that activate it made them more sensitive (Le Clec'h and colleagues, 2021). Two independent lines of evidence — chemistry and genetics — therefore point to one target.

Why people are mostly spared

The channel that praziquantel opens is a flatworm channel. The papers summarised here describe praziquantel as a potent activator of this flatworm channel; they do not set out in detail how human channels respond, so what is known about human safety comes mainly from decades of clinical use, the label and the trials described below. A practical limitation also follows from the biology: young, migrating schistosomes are less affected, which the label reflects in a warning that treatment in the early, acute phase "may not prevent progression" of the infection.

How the Body Handles It

The figures in this section come from the current United States label for praziquantel 600 milligram tablets.

Absorption and timing

About 80% of a swallowed dose is absorbed, and the highest blood level is reached one to three hours after a dose. The drug is then removed quickly: its half-life — the time for the blood level to fall by half — is only 0.8 to 1.5 hours. This short presence in the blood is one reason the label's regimens give three doses four to six hours apart in a single day.

The liver's first pass

Praziquantel "is rapidly metabolized by the cytochrome P450 enzyme system and undergoes a first pass effect." A first-pass effect means that much of the drug absorbed from the gut is broken down by the liver before it reaches the rest of the body. Cytochrome P450 3A (CYP3A), a family of liver enzymes, is the main route; a 2002 study described these as "likely to be major enzymes responsible for praziquantel metabolism" (Ridtitid and colleagues, 2002). About 80% of a dose leaves the body through the kidneys, more than 99% of it as breakdown products rather than as unchanged drug.

Food and taste

The label directs that the tablets be taken "with water during meals" and not chewed or held in the mouth, because "the bitter taste may cause gagging or vomiting." For children under six, the label allows tablets to be crushed or disintegrated and mixed with semi-solid food or liquid, used within one hour.

Liver disease changes the picture

Because the liver does most of the work, liver damage — which schistosomiasis itself can cause — raises blood levels. In a study of 40 people with Schistosoma mansoni infection described on the label, mild liver impairment made no significant difference. In moderate impairment (Child-Pugh class B, a standard grading of liver function) the total drug exposure rose about 3.6-fold, and in severe impairment (class C) about 15-fold. The label calls for monitoring for side effects in people with hepatosplenic schistosomiasis and moderate or severe liver impairment.

Schistosomiasis: The Main Use

Schistosomiasis is caused by blood flukes of the genus Schistosoma. People are infected when larvae released by freshwater snails pass through the skin. The adult worms live for years in blood vessels around the gut or bladder, "successfully evading the immune system while excreting hundreds to thousands of eggs daily" (Colley and colleagues, 2014). The damage comes from eggs trapped in tissues: anaemia, stunted growth, impaired learning, liver scarring with high blood pressure in the liver's veins, and inflammation and scarring of the urinary and genital tract. A 2025 Lancet review lists kidney failure and squamous-cell carcinoma of the bladder among the complications of the urogenital form, and states that "praziquantel is the first-line treatment" (Buonfrate and colleagues, 2025).

What the label approves

The United States label approves praziquantel for people aged one year and older with schistosomiasis "due to all species of schistosoma", naming Schistosoma mekongi, japonicum, mansoni and hematobium. The labelled regimen is 20 milligrams per kilogram of body weight three times in one day, four to six hours apart. The World Health Organization's Expert Committee report of 2025 notes that the organization's own recommendation for adults and school-aged children is a single dose of 40 milligrams per kilogram.

The trial evidence

The 2014 Cochrane review pooled 30 randomised trials with 8,165 participants in urinary schistosomiasis, most of them in children in sub-Saharan Africa. A single 40 milligram per kilogram dose reduced the share of people still passing eggs in their urine by around 60% compared with placebo one to two months later (high-quality evidence). The share of people cured varied widely between trials, from 22.5% to 83.3%, but was above 60% in five of seven trials, and egg counts fell by more than 95% in five of six trials. Splitting the dose into two over 12 hours "probably has no benefits over a single dose", and in one trial caused more vomiting and dizziness. Side effects were described as mild, though the reviewers judged the monitoring of side effects in the trials to be of generally low quality (Kramer and colleagues, 2014).

A 2023 systematic review of studies in children reported egg reduction rates of 94.2% to 99.9% for intestinal and 91.9% to 98% for urinary schistosomiasis, and cure rates of 81.2% to 99.1% and 79% to 93.7% respectively, alongside some egg reduction results that the authors describe as suggesting sub-optimal efficacy (Aboagye and Addison, 2023).

Cure, reinfection and disease

Treatment does not protect against new infection. The same 2023 review found reinfection rates of 8.1% to 39.6% for urinary and 13.9% to 63.4% for intestinal schistosomiasis within eight to 28 weeks of treatment, and its authors write that treatment needs to be accompanied by "potable water, toilet, and recreational facilities" (Aboagye and Addison, 2023). The World Health Organization's fact sheet states that "even though re-infection may occur after treatment, the risk of developing severe disease is diminished and even reversed when treatment is initiated and repeated in childhood."

Liver Flukes, Lung Flukes and Tapeworms

Chinese and Southeast Asian liver flukes

The second labelled use in the United States is clonorchiasis and opisthorchiasis, infections with the liver flukes Clonorchis sinensis and Opisthorchis viverrini, caught by eating raw or undercooked freshwater fish. The labelled regimen is 25 milligrams per kilogram three times in one day, four to six hours apart. The label notes that approval "was based on studies in which the two species were not differentiated." A 2024 review describes praziquantel-based preventive chemotherapy, "usually combined with behavioral change through information, education and communication, and environmental control", as the mainstay of control in eastern and southeastern Asia and eastern Europe (Qian and colleagues, 2024). The site's Liver Flukes and Bile Duct Cancer page reports the reinfection studies from northeast Thailand in detail.

Lung flukes

In paragonimiasis, the worms usually settle in the lungs but sometimes reach the brain or spinal cord; in Paragonimus westermani, brain infection makes up about 45% of cases outside the lungs. A 2013 neurology handbook chapter names praziquantel as the drug of choice, at 25 milligrams per kilogram three times daily for two to three days, with a second course sometimes needed in severe infections (Chai, 2013). This use is not on the United States label.

Tapeworms and brain cysts

The World Health Organization's Model List names it both among intestinal worm medicines and among cysticidal medicines — drugs that kill tapeworm cysts in tissue. The most serious cyst disease is neurocysticercosis, in which larvae of the pork tapeworm Taenia solium form cysts in the brain. It "causes a substantial burden of seizure disorders worldwide" (Garcia and colleagues, 2014).

In a 2014 double-blind randomised trial in Peru, 124 people with living cysts in the brain tissue received ten days of albendazole plus praziquantel (50 milligrams per kilogram per day), standard albendazole alone, or a higher dose of albendazole alone. Six months later, brain scans showed complete cyst resolution in 64% of the combination group against 37% of the standard albendazole group; side effects did not differ significantly between groups (Garcia and colleagues, 2014).

The 2017 clinical practice guideline of the Infectious Diseases Society of America and the American Society of Tropical Medicine and Hygiene recommends albendazole (15 milligrams per kilogram per day) combined with praziquantel (50 milligrams per kilogram per day) for 10 to 14 days, rather than albendazole alone, for patients with more than two living cysts in the brain tissue — a strong recommendation based on moderate-quality evidence. For people with one or two living cysts, the same guideline recommends albendazole on its own (White and colleagues, 2018). The guideline also recommends steroid treatment alongside antiparasitic drugs for living brain cysts, because dying cysts provoke inflammation. The United States label lists cysticercosis in the eye as a contraindication and calls for hospital admission when a fluke infection is found together with brain cysticercosis. More detail is on the site's Praziquantel and Albendazole for Tapeworm and Neurocysticercosis Treatment pages.

Mass Drug Administration and the 2022 World Health Organization Guideline

In mass drug administration, everyone in an at-risk group — often every child in a school, sometimes a whole village — is given the drug without an individual test. The World Health Organization calls this approach "preventive chemotherapy." In 2001, World Health Assembly resolution 54.19 set a global strategy built on it, and the organization's 2006 guidelines recommended regular praziquantel mass treatment, mainly of school-aged children (Lo and colleagues, 2022). In 2014, reviewers summarised the result as treatment "once every 1 or 2 years" to suppress disease (Colley and colleagues, 2014).

The scale

The World Health Organization's schistosomiasis fact sheet reports that at least 253.7 million people required preventive treatment in 2024 and that more than 100.5 million were reported treated. It gives the share reached as 39.6% globally and 61.7% for school-aged children, and names "the limited availability of praziquantel, particularly for the treatment of adults" as a major limitation. It also states that enough praziquantel to treat more than 100 million school-aged children per year has been pledged by the private sector and development partners. The fact sheet describes praziquantel as "effective, safe and low-cost."

The 2022 guideline

In February 2022 the World Health Organization published a new guideline on the control and elimination of human schistosomiasis, with six recommendations. A review written by its development group summarises the main changes as "expansion of preventive chemotherapy eligibility from the predominant group of school-aged children to all age groups (2 years and older), lowering the prevalence threshold for annual preventive chemotherapy, and increasing the frequency of treatment" (Lo and colleagues, 2022). The guideline's goals are elimination of schistosomiasis as a public-health problem everywhere and interruption of transmission in selected countries.

What mass treatment has not done

Two cluster-randomised trials, in Zanzibar and Côte d'Ivoire, tested whether years of mass praziquantel treatment could stop transmission of urogenital schistosomiasis in low-prevalence areas. The trials showed that several years of mass praziquantel treatment failed to interrupt transmission, even when it was given twice a year. The authors conclude that clean water, sanitation, snail control and behaviour-change communication will probably be needed as well (Campbell and colleagues, 2020).

Young Children and Arpraziquantel

For years the youngest children were left out of treatment campaigns. A 2012 study noted that in 2012 the World Health Organization had formally recognised that infants and preschool children are at significant risk of schistosomiasis and qualify for treatment. In that Ugandan study, of 305 children aged five months to seven years who were followed up, 56.4% were cured; side effects were mild and passed. Cure was 77.6% in children who had never been treated but 41.7% in those who had received one to four treatments in the previous 18 months (Sousa-Figueiredo and colleagues, 2012). The standard tablet is large and bitter, and has to be broken, crushed and mixed for small children.

The phase 3 trial

Arpraziquantel is a dispersible tablet containing only the active R-form of praziquantel. In an open-label, partly randomised phase 3 trial in Côte d'Ivoire and Kenya, 288 children aged three months to six years were treated. Among children aged four to six with Schistosoma mansoni, cure rates were 87.8% with a single arpraziquantel dose of 50 milligrams per kilogram and 81.3% with standard praziquantel at 40 milligrams per kilogram. "No safety concerns were identified"; the most common drug-related side effects were abdominal pain (14%), diarrhoea (9%), drowsiness (7%) and vomiting (6%) (N'Goran and colleagues, 2023). The trial was funded partly by the developer.

Regulatory steps

On 15 December 2023 the European Medicines Agency's human medicines committee adopted a positive scientific opinion on arpraziquantel for children aged three months to six years. This was not a licence for Europe: it was given under a procedure for medicines intended for use outside the European Union. The World Health Organization's 2025 Expert Committee report records that arpraziquantel 150 milligram dispersible tablets were included in the World Health Organization List of Prequalified Medicines in May 2024, and the Committee recommended adding arpraziquantel to the Essential Medicines List for Children as a therapeutic alternative to praziquantel. The same report records the reservations of the organization's own neglected tropical diseases department, which considered the listing premature because the product was not yet available, its strength meant many tablets per dose, and it would have to be bought, whereas praziquantel is donated.

Falling Cure Rates and Resistance Research

When one drug is given to hundreds of millions of people, year after year, against parasites that reproduce in huge numbers, scientists watch for resistance. In 2014, reviewers wrote that "the development of drug resistance is a much feared possibility" and that none of the many compounds tested so far "represents a suitable substitute or adjunct to praziquantel" (Cioli and colleagues, 2014). A 2016 review found "no additional candidates currently in the anti-schistosome drug clinical trial pipeline" (Trainor-Moss and Mutapi, 2016). The World Health Organization's Model List keeps one older drug, oxamniquine, on its complementary list "for use when praziquantel treatment fails."

Low cure rates are not the same as resistance

A low cure rate can have several causes: heavy infections, immature worms that the drug handles poorly, rapid reinfection, or tests that miss light infections. A trial in Côte d'Ivoire showed how much the test matters. In 125 children with Schistosoma mansoni, a single dose cured 64% by standard stool microscopy, 45% by a genetic test of stool, and only 16% by a highly sensitive urine test that detects a substance released by living worms. Four doses two weeks apart did little better on the worm test (18%). The authors concluded that egg-based tests had overestimated the drug's efficacy and that "active Schistosoma infections are still present despite multiple treatments" (Hoekstra and colleagues, 2022). This is a finding about cure as measured by sensitive tests, not a demonstration of resistance.

What parasite genetics shows

In Uganda, where reduced praziquantel efficacy had been documented, whole-genome sequencing of 198 parasite larvae from 34 children found that "a single round of treatment did not reduce this diversity", with "no apparent population contraction caused by long-term praziquantel use" and "no high frequency functionally impactful variants" (Berger and colleagues, 2021). A larger 2026 study of 570 parasite samples from eight countries tested natural versions of the calcium channel described above. It found four naturally occurring variants associated with reduced praziquantel sensitivity, "indicating standing variation for resistance", and identified instances of treatment failure in samples taken from people before and after treatment, "supporting the potential for praziquantel resistance" (Berger and colleagues, 2026). Laboratory-selected resistant worms carry changes at the same channel (Le Clec'h and colleagues, 2021).

Taken together, the research describes the genetic ingredients for resistance already present in wild parasites and isolated treatment failures, but not widespread resistance in the field. The 2026 authors call for genomic surveillance and adaptive treatment strategies.

Cancer: What the Research Does and Does Not Show

Two of the infections praziquantel treats are classed as causes of cancer. Chronic urogenital schistosomiasis is linked to squamous-cell carcinoma of the bladder (Buonfrate and colleagues, 2025), and chronic liver fluke infection to cholangiocarcinoma, cancer of the bile ducts (Qian and colleagues, 2024). Praziquantel removes the worms. Whether removing them lowers the cancer rate is a separate question.

The site's two cancer pages examine that question in detail. The Schistosoma and Bladder Cancer page reports that no randomised trial was found that measured whether praziquantel lowers the rate of bladder cancer itself, that such a trial would take decades, and that the evidence that treatment and control lower cancer risk is indirect — for example, reversal of urinary-tract damage in treated children. The Liver Flukes and Bile Duct Cancer page reports that no study found shows that clearing the fluke prevents cancer once damage is established; in a five-year follow-up in Thailand, more than a third of treated people with advanced bile duct scarring still had or relapsed into advanced scarring after treatment.

Praziquantel is not an approved cancer treatment, and none of the studies listed on this page tested it as one. On the question of whether the drug itself could cause cancer, the label reports that long-term studies in rats and golden hamsters "did not reveal any carcinogenic effect" at the doses tested, while studies of its effects on genes (mutagenicity) are described as "inconclusive" — animal and laboratory findings, not human data.

Safety Findings

Common effects

The United States label lists the side effects seen in adults and children as malaise, fever, headache, dizziness, abdominal discomfort, nausea and hives (urticaria), and notes that they "may be more frequent and/or serious in patients with a heavy worm burden" — a pattern consistent with reactions to dying worms. Reports from worldwide use add vomiting, abdominal pain, bloody diarrhoea, vertigo, drowsiness, itching, rash, rare severe allergic reactions including anaphylaxis, and Stevens-Johnson syndrome, a rare severe skin reaction. Trials in children have described side effects as mild and short-lived (Sousa-Figueiredo and colleagues, 2012; N'Goran and colleagues, 2023).

Warnings on the label

Drug interactions

Because the liver's cytochrome P450 3A enzymes break praziquantel down, drugs that speed up these enzymes can wipe out its effect. In a 2002 crossover study in ten healthy volunteers, five days of the tuberculosis drug rifampin lowered blood praziquantel after a single dose to undetectable levels in seven of ten people (Ridtitid and colleagues, 2002). The label makes strong inducers of these enzymes, such as rifampin, a contraindication, "since therapeutically effective levels of praziquantel are unlikely to be achieved." The label reports that efavirenz, a drug for human immunodeficiency virus infection and a moderate inducer of these enzymes, cut praziquantel exposure by 77% in 20 volunteers, and advises against combining the two. In the other direction, enzyme-blocking drugs such as cimetidine, ketoconazole, itraconazole, erythromycin and ritonavir may raise praziquantel levels, and grapefruit juice was reported to raise peak levels 1.6-fold and total exposure 1.9-fold.

Pregnancy and breastfeeding

In a randomised, double-blind, placebo-controlled trial in the Philippines, 370 pregnant women with Schistosoma japonicum were given praziquantel or placebo at 12 to 16 weeks of pregnancy. Praziquantel "did not have a significant effect on birthweight" (2.85 kilograms in both groups), and there were "no significant differences in key safety outcomes including abortion, fetal death in utero, and congenital anomalies" (Olveda and colleagues, 2016). The label summarises this trial and a second in 2,507 pregnant women in Uganda, and states that published studies "have not identified an association with praziquantel use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes." Limited reports find praziquantel in human milk at low concentrations; there is no information on effects in the breastfed infant.

Young infants

The label states that safety in children younger than one year "has not been established." The 2025 World Health Organization Expert Committee report described the arpraziquantel safety data in children two years and younger as limited, with uncertainty "particularly relevant for children younger than 1 year."

What Is Not Known

Connections

Key Research Papers

  1. Gönnert R, Andrews P. Praziquantel, a new board-spectrum antischistosomal agent. Zeitschrift fur Parasitenkunde (Berlin, Germany). 1977;52(2):129-50. PubMed PMID: 410178
  2. Waechtler A, Cezanne B, Maillard D, et al. Praziquantel - 50 Years of Research. ChemMedChem. 2023;18(12):e202300154. PubMed PMID: 37009677
  3. Woelfle M, Seerden JP, de Gooijer J, et al. Resolution of praziquantel. PLoS Neglected Tropical Diseases. 2011;5(9):e1260. PubMed PMID: 21949890
  4. Park SK, Gunaratne GS, Chulkov EG, et al. The anthelmintic drug praziquantel activates a schistosome transient receptor potential channel. The Journal of Biological Chemistry. 2019;294(49):18873-18880. PubMed PMID: 31653697
  5. Park SK, Friedrich L, Yahya NA, et al. Mechanism of praziquantel action at a parasitic flatworm ion channel. Science Translational Medicine. 2021;13(625):eabj5832. PubMed PMID: 34936384
  6. Le Clec'h W, Chevalier FD, Mattos ACA, et al. Genetic analysis of praziquantel response in schistosome parasites implicates a transient receptor potential channel. Science Translational Medicine. 2021;13(625):eabj9114. PubMed PMID: 34936381
  7. Colley DG, Bustinduy AL, Secor WE, et al. Human schistosomiasis. Lancet. 2014;383(9936):2253-64. PubMed PMID: 24698483
  8. Buonfrate D, Ferrari TCA, Adegnika AA, et al. Human schistosomiasis. Lancet. 2025;405(10479):658-670. PubMed PMID: 39986748
  9. Kramer CV, Zhang F, Sinclair D, et al. Drugs for treating urinary schistosomiasis. The Cochrane Database of Systematic Reviews. 2014;2014(8):CD000053. PubMed PMID: 25099517
  10. Aboagye IF, Addison YAA. Praziquantel efficacy, urinary and intestinal schistosomiasis reinfection - a systematic review. Pathogens and Global Health. 2023;117(7):623-630. PubMed PMID: 36394218
  11. Cioli D, Pica-Mattoccia L, Basso A, et al. Schistosomiasis control: praziquantel forever? Molecular and Biochemical Parasitology. 2014;195(1):23-9. PubMed PMID: 24955523
  12. Qian M-B, Keiser J, Utzinger J, et al. Clonorchiasis and opisthorchiasis: epidemiology, transmission, clinical features, morbidity, diagnosis, treatment, and control. Clinical Microbiology Reviews. 2024;37(1):e0000923. PubMed PMID: 38169283
  13. Chai JY. Paragonimiasis. Handbook of Clinical Neurology. 2013;114:283-96. PubMed PMID: 23829919
  14. Garcia HH, Gonzales I, Lescano AG, et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. The Lancet Infectious Diseases. 2014;14(8):687-695. PubMed PMID: 24999157
  15. White AC Jr, Coyle CM, Rajshekhar V, et al. Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). The American Journal of Tropical Medicine and Hygiene. 2018;98(4):945-966. PubMed PMID: 29644966
  16. Lo NC, Bezerra FSM, Colley DG, et al. Review of 2022 WHO guidelines on the control and elimination of schistosomiasis. The Lancet Infectious Diseases. 2022;22(11):e327-e335. PubMed PMID: 35594896
  17. Campbell CH, Binder S, King CH, et al. SCORE Operational Research on Moving toward Interruption of Schistosomiasis Transmission. The American Journal of Tropical Medicine and Hygiene. 2020;103(1_Suppl):58-65. PubMed PMID: 32400354
  18. Sousa-Figueiredo JC, Betson M, Atuhaire A, et al. Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. PLoS Neglected Tropical Diseases. 2012;6(10):e1864. PubMed PMID: 23094120
  19. N'Goran EK, Odiere MR, Assandé Aka R, et al. Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with Schistosoma in Côte d'Ivoire and Kenya: an open-label, partly randomised, phase 3 trial. The Lancet Infectious Diseases. 2023;23(7):867-876. PubMed PMID: 36893784
  20. Trainor-Moss S, Mutapi F. Schistosomiasis therapeutics: whats in the pipeline? Expert Review of Clinical Pharmacology. 2016;9(2):157-60. PubMed PMID: 26508363
  21. Hoekstra PT, Casacuberta-Partal M, van Lieshout L, et al. Limited efficacy of repeated praziquantel treatment in Schistosoma mansoni infections as revealed by highly accurate diagnostics, PCR and UCP-LF CAA (RePST trial). PLoS Neglected Tropical Diseases. 2022;16(12):e0011008. PubMed PMID: 36548444
  22. Berger DJ, Crellen T, Lamberton PHL, et al. Whole-genome sequencing of Schistosoma mansoni reveals extensive diversity with limited selection despite mass drug administration. Nature Communications. 2021;12(1):4776. PubMed PMID: 34362894
  23. Berger DJ, Park SK, Crellen T, et al. Extensive parasite transmission and variation in a functional receptor associated with drug resistance in endemic Schistosoma mansoni. Science Advances. 2026;12(29):eadt3721. PubMed PMID: 42467774
  24. Ridtitid W, Wongnawa M, Mahatthanatrakul W, et al. Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clinical Pharmacology and Therapeutics. 2002;72(5):505-13. PubMed PMID: 12426514
  25. Olveda RM, Acosta LP, Tallo V, et al. Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Infectious Diseases. 2016;16(2):199-208. PubMed PMID: 26511959

PubMed Topic Searches

  1. PubMed: praziquantel schistosomiasis trials
  2. PubMed: praziquantel and the worm calcium channel
  3. PubMed: praziquantel resistance
  4. PubMed: arpraziquantel
  5. PubMed: praziquantel neurocysticercosis
  6. PubMed: praziquantel liver flukes

Other Sources

  1. United States label, praziquantel 600 milligram film-coated tablets (revised June 2026). DailyMed. dailymed.nlm.nih.gov
  2. World Health Organization, schistosomiasis fact sheet. who.int
  3. World Health Organization, guideline on control and elimination of human schistosomiasis, 2022. who.int
  4. World Health Organization, Model List of Essential Medicines, 24th list, 2025. iris.who.int
  5. World Health Organization, The selection and use of essential medicines 2025, Technical Report Series 1064 (arpraziquantel evaluation, prequalification and listing). iris.who.int
  6. European Medicines Agency, "New treatment for young children with parasitic disease schistosomiasis", 15 December 2023. ema.europa.eu
  7. World Health Organization, departmental update on the European Medicines Agency's positive scientific opinion on arpraziquantel, 7 February 2024. who.int